Newsroom

Elektronenmikroskopische Aufnahme von Viruspartikeln des Grippeerregers Influenza.

News

Annual flu vaccines protect against severe infection, but they vary in efficacy and may not match the most virulent strains of the season. The reality of a universal flu vaccine, which would protect people from all strains, and ideally longer than a single season, remains elusive. This major roadblock is addressed by the INCENTIVE consortium, which is funded by the European Commission and coordinated at the Helmholtz Centre for Infection Research (HZI) by Prof. Carlos A. Guzman. Findings published in the Journal of Virology suggest that universal flu vaccines are coming closer.

10.09.2024

HZI Campus

Interview

A key focus at the Helmholtz Centre for Infection Research (HZI) and its sites like the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) is translating research findings into medical and pharmaceutical applications. Beyond scientific collaboration, the goal is to facilitate the transfer of technology and knowledge into practical and potentially commercial uses. Recently, the company MyxoTech has been founded as a HIPS spin-off. MyxoTech CEO Peter Sullivan explains what the new company is about and what it wants to achieve.

29.08.2024

HIPS

Group photo 4 scientists with a large cheque

News

Yesterday, the lighthouse project of the state of Lower Saxony reached its latest milestone: At the second portfolio conference of the Institute for Biomedical Translation (IBT) Lower Saxony, a high-caliber jury selected projects from the Helmholtz Centre for Infection Research and the Hannover Medical School that will receive funding of over 1.6 million euros. A total of 25 million euros are available to the IBT Lower Saxony until 2028 to accelerate the transfer of cutting-edge research in the life sciences in Lower Saxony and to bring it out into the world in the form of startups and entrepreneurial ideas.

28.08.2024

HZI Campus

Marco Galardini (left) and Maureen Obara in the lab.

News

Certain changes in the genetic material of pathogens can alter their ability to infect human cells or protect them better from defense by the immune system. Researchers were able to observe this effect particularly impressive in the SARS-CoV-2 virus. During the coronavirus pandemic, an interdisciplinary team at TWINCORE, Centre for Experimental and Clinical Infection Research in Hanover, investigated the interaction between pairs of mutations that might have triggered several of these changes in infectivity and immune escape. They have now published their findings in the journal Genome Biology. The TWINCORE is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Hannover Medical School (MHH).

23.08.2024

TWINCORE

HZI Campus

Interview

The current outbreak of the Mpox virus originated in Central Africa. A first case has now been discovered in Europe. The WHO has declared the highest alert level. In an interview with Helmholtz, Fabian Leendertz, Director of the Helmholtz Institute for One Health (HIOH), puts the events in context.

23.08.2024

HIOH

News

The protective effect of established COVID-19 vaccines is initially very robust, but wanes relatively quickly. This limitation imposes a need for periodic booster shots, which drives vaccine hesitation. In contrast, an innovative vector vaccine developed at the Helmholtz Centre for Infection Research (HZI) presents a compelling alternative. It elicits prolonged immune response in animal models, and maintains its efficacy over extended time. The concept employs an animal cytomegalovirus (MCMV; murine cytomegalovirus) as the vector that expresses and delivers the coronavirus spike protein information. Crucially, this vector poses no threat to humans, enhancing the vaccine's safety profile.

20.08.2024

HZI Campus

Back to the first page
...
32
33
34
35
...
161

HZI in the media

... zunehmen. Mit der Gründung des HIOH im Jahr 2021 als Standort des Braunschweiger Helmholtz-Zentrums für ...

31.08.2026

Management & Krankenhaus

... des neuen Forschungsgebäudes des Helmholtz-Instituts für One Health (HIOH) in Greifswald (Landkreis Vorpommern-Greifswald) gelegt

. ...

28.08.2026

Tagesschau

How Bacteria Develop Resistance to Antisense Antibiotics—and How Future Therapies Can Be Made Less Susceptible to It

28.08.2026

Bionity.COM

Wie man sich mit Mpox anstecken kann und warum sich Personen mit häufig wechselnden Sexpartnern impfen lassen sollten.

28.08.2026

Apotheken Umschau

Infection Research; the RESIST Cluster of Excellence; and the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg has

27.08.2026

Phys.org

... Arbeiten am Universitätsklinikum Köln und am Helmholtz-Zentrum für Infektionsforschung startet nun die Entwicklung und GMP- ...

26.08.2026

healthcare-in-europe.com

Infos: Herpesviren – Eine große Familie Helmholtz Zentrum für Infektionsforschung www.helmholtz-hzi.de/wissen/wissensportal/ ...

25.08.2026

SWR4 Rheinland-Pfalz

An einer weiteren Station veranschaulicht das Helmholtz-Institut für Pharmazeutische Forschung, wie die Entwicklung neuer ...

25.08.2026

MSN Deutschland

Technologien“ im HUMAN-Projekt am Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig . Im Mittelpunkt ihrer Arbeit steht ...

23.08.2026

Regional Heute

... Medizinischen Hochschule Hannover (MHH) und des Helmholtz-Zentrums für Infektionsforschung (HZI). Dafür setzten die Forschenden sechs ...

19.08.2026

Pharmazeutische Zeitung

... Arbeiten am Universitätsklinikum Köln und am Helmholtz-Zentrum für Infektionsforschung startet nun die Entwicklung und GMP- ...

19.08.2026

DeutschesGesundheitsPortal

available genomic resources. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.

14.08.2026

News Medical

Register now for the HZI newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.